Lantern Pharma to Present New Preclinical Data at Three Upcoming Scientific Conferences
October 25 2022 - 8:00AM
Business Wire
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence ("A.I.") and machine learning (“M.L.”) platform to
transform the cost, pace, and timeline of oncology drug discovery
and development, today announced that the Company will present new
preclinical data at three upcoming scientific conferences:
- Society of Neuro Oncology Annual Meeting in Tampa, FL on
November 18, from 7:30-9:30 p.m. ET. Poster Title:
Preclinical efficacy of LP-184, a tumor site activated
synthetically lethal therapeutic, in glioblastoma
Registration:
https://www.soc-neuro-onc.org/WEB/Event_Content/Annual_Meeting/Annual_Conference.aspx
- San Antonio Breast Cancer Symposium in San Antonio, TX
on December 8, from 8:00-9:15 a.m. ET. Poster Title: To be
announced Registration:
https://www.sabcs.org/2022-Registration
- American Society of Hematology Annual Meeting in
New Orleans, LA on December 10, from 6:30-8:30 p.m. ET. Poster
Title: To be announced Registration:
https://www.hematology.org/meetings/annual-meeting/registration-information
Further details on the new preclinical data as well as
additional conference presentation details will be announced in the
coming weeks.
About Lantern Pharma: Lantern Pharma (NASDAQ: LTRN) is a
clinical-stage oncology-focused biopharmaceutical company
leveraging its proprietary RADR® A.I. and machine learning platform
to discover biomarker signatures that identify patients most likely
to respond to its pipeline of genomically-targeted therapeutics.
Lantern is currently developing four drug candidates and an ADC
program across nine disclosed tumor targets, including two phase 2
programs. By targeting drugs to patients whose genomic profile
identifies them as having the highest probability of benefiting
from the drug, Lantern's approach represents the potential to
deliver best-in-class outcomes.
Please find more information at: Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/ Twitter:
@lanternpharma
Forward-looking Statements: This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying drug candidates and
patient populations that are likely to respond to a drug candidate;
our strategic plans to advance the development of our drug
candidates and antibody drug conjugate (ADC) development program;
estimates regarding the development timing for our drug candidates
and ADC development program; expectations and estimates regarding
clinical trial timing and patient enrollment; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the drug
development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate; estimates regarding patient
populations, potential markets and potential market sizes; sales
estimates for our drug candidates and our plans to discover and
develop drug candidates and to maximize their commercial potential
by advancing such drug candidates ourselves or in collaboration
with others. Any statements that are not statements of historical
fact (including, without limitation, statements that use words such
as "anticipate," "believe," "contemplate," "could," "estimate,"
"expect," "intend," "seek," "may," "might," "plan," "potential,"
"predict," "project," "target," "model," "objective," "aim,"
"upcoming," "should," "will," "would," or the negative of these
words or other similar expressions) should be considered
forward-looking statements. There are a number of important factors
that could cause our actual results to differ materially from those
indicated by the forward-looking statements, such as (i) the impact
of the COVID-19 pandemic, (ii) the risk that our research and the
research of our collaborators may not be successful, (iii) the risk
that none of our product candidates has received FDA marketing
approval, and we may not be able to successfully initiate, conduct,
or conclude clinical testing for or obtain marketing approval for
our product candidates, (iv) the risk that no drug product based on
our proprietary RADR® A.I. platform has received FDA marketing
approval or otherwise been incorporated into a commercial product,
and (v) those other factors set forth in the Risk Factors section
in our Annual Report on Form 10-K for the year ended December 31,
2021, filed with the Securities and Exchange Commission on March
10, 2022. You may access our Annual Report on Form 10-K for the
year ended December 31, 2021 under the investor SEC filings tab of
our website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221025005214/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024